HG 302
Alternative Names: HG-302Latest Information Update: 25 Sep 2024
At a glance
- Originator HuidaGene Therapeutics
- Class Gene therapies
- Mechanism of Action Dystrophin expression modulators; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Duchenne muscular dystrophy
Most Recent Events
- 19 Sep 2024 HuidaGene Therapeutics plans a phase 0 MUSCLE trial for Duchenne muscular dystrophy (In children) in October 2024 (IV) (NCT06594094)
- 19 Dec 2023 HuidaGene has patent protection for Cas12i proteins in USA
- 19 Dec 2023 The US FDA grants Rare Pediatric Designation to HG 302 for Duchenne muscular dystrophy